



ArmaGen to Present at Oppenheimer 25th Annual Healthcare Conference

Calabasas, Calif., December 3, 2014 – ArmaGen, a privately held biotechnology company focused on developing revolutionary therapies to treat severe neurological disorders, announced today that James E. Callaway, Ph.D., Chief Executive Officer, will present an overview of the Company at the Oppenheimer 25th Annual Healthcare Conference in New York City on Thursday, December 11, 2014 at 2:45 p.m. EST.

The Oppenheimer Healthcare Conference features presentations from a core group of public and private companies who are leaders and pioneers in the pharmaceutical, biotechnology, medical device, healthcare facility, health technology and distribution, provider and service industries.

About ArmaGen

ArmaGen, Inc. is a privately held biotechnology company focused on developing revolutionary therapies for severe neurological disorders. The company is developing a robust pipeline of innovative therapies for the treatment of neurological complications of lysosomal storage disorders such as Hunter syndrome, Hurler syndrome, metachromatic leukodystrophy and Sanfilippo A syndrome, as well as central nervous system diseases such as Alzheimer's and Parkinson's. ArmaGen's pipeline is based on decades of scientific leadership in engineering therapies to cross the blood-brain barrier and a dominant intellectual property portfolio. The company is advancing its pipeline through licensing and collaboration agreements, in-house development programs, and future partnering opportunities. For more information, visit www.armagen.com.

###

Contacts:

ArmaGen, Inc.

Derek Kelaita
Vice President, Business Development
818-252-8200
dkelaita@armagen.com

For media inquiries:

Smitha Dwarakanath
SmithSolve LLC
973-442-1555 ext. 122
smitha.dwarakanath@smithsolve.com